* Jame Abraham, MD, FACP, as Director of the Breast Cancer Program at Cleveland Clinic's Taussig Cancer Institute. Prior to joining Cleveland Clinic, Abraham was the first Bonnie Wells Wilson Distinguished Professor and Eminent Scholar in breast cancer research and section chief of Hematology/Oncology at West Virginia University. He is also National Study Chair of the National Surgical Adjuvant Breast and Bowel Project FB-9 clinical trial studying the role of eribulin in early-stage breast cancer.
George Washington University Cancer Institute has been awarded a $2.1 million collaborative agreement over the next five years to work with the Centers for Disease Control and Prevention to design and implement a comprehensive technical assistance plan to support CDC-funded Comprehensive Cancer Control programs across the country.
“Working with the CDC, we will prioritize training needs and support implementation of proven strategies to reduce the burden of cancer in this country,” Mandi Pratt-Chapman, MA, Associate Director of GWCI and the principal investigator for the award, said in a news release. “We are also pleased to be working with the National Area Health Education Center and their local affiliates to broadly integrate cancer prevention with other chronic disease prevention activities.”
Yale Cancer Center's designation as a National Cancer Institute Comprehensive Cancer Center has been extended for an additional five years. The award includes $12.2 million in funding over the next five years to support the Center's seven research programs and eight shared resources, along with the continuation of the Center's comprehensive status.
Jean-Charles Soria, MD, PhD, has been named Editor-in-Chief of the European Society for Medical Oncology's Annals of Oncology. He will begin the role in January.
A medical oncologist with expertise in lung cancer, he was recently appointed Chair of the new Drug Development Department at Gustave Roussy Cancer Center in Paris. He has been Professor of Oncology at South Paris University since 2006, and heads a group of eight researchers at INSERM.
“Precision medicine is transforming cancer therapy, forcing us to rethink both how we manage the disease and how we teach our discipline. It's an exciting time to work in and to report on,” Soria said in a news release. “With Annals we will solicit articles on cutting-edge topics such as targets in oncology and novel immunomodulatory agents, reflecting the new molecular/genetic paradigm in oncology.”
New Pancreatic Cancer Research Initiative at OHSU
Oregon Health & Science University has launched a clinical and translational science initiative against lethal pancreatic cancers and other pancreatic diseases.
“Multidisciplinary collaborative science is the new model for academic medical research, and this initiative clearly shows just how important philanthropists will be in driving those kinds of projects in the future,” OHSU President Joe Robertson, MD, MBA, said in a news release.
Brett C. Sheppard, MD, the William E. Colson Chair for Pancreatic Disease Research and Vice Chair of Surgery at OHSU, will facilitate linking the clinical aspects, surgical care, and research programs of the initiative with the laboratories of three Knight Cancer Institute researchers:
* Lisa M. Coussens, PhD, the Hildegard Lamfrom Chair in Basic Science, Chair of OHSU's Department of Cell and Developmental Biology, and Associate Director for Basic Research for the Knight Cancer Institute;
* Joe W. Gray, PhD, the Gordon Moore Chair of Biomedical Engineering, Associate Director for translational research in the Knight Cancer Institute, and the Director of the OHSU Center for Spatial Systems Biomedicine; and
* Rosalie C. Sears, PhD, Professor in OHSU's Department of Molecular and Medical Genetics and the Cancer Biology Program Leader at the Knight Cancer Institute.
The new initiative is funded by a $25 million philanthropic pledge made by a partnership between Norma and Linda Brenden and the Colson Family Foundation over five years.
New Radiation Oncology Center at Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center has opened a 12,500-square-foot Irving Radiation Oncology Center, which is part of the medical center's Herbert Irving Comprehensive Cancer Center.
“This new technology offers greater customization and allows for a dramatically reduced treatment course, from weeks to days,” K.S. Clifford Chao, MD, Radiation Oncologist-in-Chief at New York-Presbyterian/Columbia and NewYork-Presbyterian/Weill Cornell and the Chu H. Chang Distinguished Professor and Chair of radiation oncology at Columbia University Medical Center, said in a news release.
The new center is funded in part with the support of the hospital's life trustee Herbert Irving, for whom the Cancer Center is named, and his wife, Florence. Mr. and Mrs. Irving have given more than $200 million to New York-Presbyterian Hospital and Columbia University Medical Center in support of cancer care and research.
In addition to the gift for the radiation oncology center, the Irvings recently pledged $60 million to New York-Presbyterian and Columbia University Medical Center to support research, operations, and recruitment—including the recruitment of five clinician-scientists in leukemia and blood-related cancers—as well as construction of the 9,400-square-foot Irving Bone Marrow Transplant Unit, scheduled to open next year.
Share Your News!
Send information and photos for this column to OT@LWWNY.com© 2013 by Lippincott Williams & Wilkins, Inc.
More on ONCOLOGY-TIMES.com...